Kanker komt vaak voor bij ouderen, maar door de afnemende biologische fitheid en de frequent aanwezige comorbiditeit verdragen ouderen de cytostatische behandelingen minder goed. Ouderen met tumoren hebben daardoor minder goede overlevingskansen. Sinds de introductie van immune checkpoint inhibitors (ICI) beschikken we over een nieuwe behandeloptie, met aangrijpingspunt en toxiciteitsprofiel die totaal verschillen van cytostatica. Eerder werd op onze site de aandacht gevestigd op onverwachte risico’s van ICI, met name hyperprogressie van de tumor en mortaliteit bij het combineren van immunologisch actieve medicijnen. In welke mate ICI op hogere leeftijd effectief en veilig zijn, is een ander punt van discussie.
Bronnen:
- Bouchlaka MN, Murphy WJ. Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models. Oncoimmunol. 2013; 2: e27186 ,Fulop T, Larbi A, Kotb R, Pawelec G. Immunology of aging and cancer development. Interdiscip Top Gerontol 2013; 38:38-48,Bouchlaka MN, Schisel GD, Chen M, et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med 20; 210: 2223-7,Qin A, Street L, Cease K, et al. Clinical determinants of durable clinical benefit of pembrolizumab in veterans with advanced non-small-cell lung cancer. Clin Lung Cancer 2017; 18: 559-64,Funakoshi T, Muss H, Moschos S. Comparison of efficacy of immune checkpoint inhibitors (ICI) between younger and older patients: A meta-analysis of randomized controlled trials. Cancer Immunol Res 2016; 1 suppl A, 159 ,Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treat Rev 2016: 45; 30-7,Saba NF, Blumenstein GR, Gurgay J, at al. Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of Checkmate 141 by age. 2018 ASCO Annual Meeting, June 1-5, Chicago, Abstr 6028,Landre T, Taleb C, Nicolas P, Des Guetz G. Is there clinical benefit of anti-PD1 in patients older than 75 years with previously treated solid tumour? J Clin Oncol 2017; 34 (suppl 15), 3070,Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B. Immunosenescence and immune checkpoint inhibitors in non-small cell lung cancer patients: does age really matter? Cancer Treat Rev 2017; 60: 60-8,Orloff M. Melanoma immunotherapy in the elderly. Curr Oncol Rep 2018; 20: 20. Doi: 10.1007/s11912-018-0656-3,Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35.,Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39,Kugel CH 3rd, Douglass SM, Webster MR, et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res 2018 doi: 10.1158/1078-0432. CCR-18-1116,Friedman C, Horvat T, Minehart L, et al. Efficay and safety of checkpoint blockage of advanced melanoma in patients age 80 and older (80+).J Clin Oncol 2016; 34, suppl: abstr 10009,Johnpulle RA, Conry RM, Sosman JA, Puzanov, Johnson DB. Responses to immune checkpoint inhibitors in nonagenarians. Oncoimmunol 2016; 5: e1234572. Doi: 10.1080/2162402X.2016.1234572